Skip to main content

Table 2 Association between TopIIα and Ki67 expression and clinical variables

From: Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer

Clinical variables TopIIα expression (%) P Ki67 expression (%) P
  High Low   High Low  
Sex       
   Male 25 (22.5) 86 (77.5) 0.998 39 (35.1) 72 (64.9) 0.584
   Female 9 (22.5) 31 (77.5)   16 (40.0) 24 (60.0)  
Smoking status       
   No 16 (24.6) 49 (75.4) 0.591 25 (38.5) 40 (61.5) 0.651
   Yes 18 (20.9) 68 (79.1)   30 (34.9) 56 (65.1)  
Histology       
   Adenocarcinoma 14 (23.7) 45 (76.3) 0.775 22 (37.3) 37 (62.7) 0.860
   Non- adenocarcinoma 20 (21.7) 72 (78.3)   33 (35.9) 59 (64.1)  
Stage       
   I 10 (18.5) 44 (81.5) 0.177 13 (24.1) 41 (75.9) 0.034*
   II 15 (31.9) 32 (68.1)   23 (48.9) 24 (51.1)  
   III 9 (18.0) 41 (82.0)   19 (38.0) 31 (62.0)  
T stage       
T1 13 (34.2) 25 (65.8) 0.148 18 (47.4) 20 (52.6) 0.168
T2 18 (18.2) 81 (81.8)   34 (34.3) 65 (65.7)  
T3-4 3 (21.4) 11 (78.6)   3 (21.4) 11 (78.6)  
N stage       
N0 12 (19.4) 50 (80.6) 0.137 16 (25.8) 46 (74.2) 0.065
N1 16 (32.0) 34 (68.0)   23 (46.0) 27 (54.0)  
N2 6 (15.4) 33 (84.6)   16 (41.0) 23 (59.0)  
  1. * P < 0.05 was considered statistically significant